Physician profile
John Matthew Smith
NPI 1932192713
$1,220.78
in general payments reported to CMS, 2019-2025
32 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $67.44 · 2021: $291 · 2022: $128 · 2023: $273 · 2024: $168 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $182.11 | 2019-2020 | |
| Lundbeck LLC | $91.79 | 2023-2025 | Vyepti, Rexulti |
| Novo Nordisk INC | $86.81 | 2020-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $77.43 | 2021-2022 | |
| Abbvie INC. | $61.77 | 2021 | |
| Glaxosmithkline, LLC. | $54.59 | 2021-2023 | Shingrix |
| Alexion Pharmaceuticals, INC. | $50.78 | 2023 | Ultomiris |
| Merck Sharp & Dohme LLC | $42.57 | 2021-2023 | Keytruda |
| Janssen Biotech, INC. | $39.63 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.00 | 2019-2021 | |
| Lilly USA, LLC | $38.04 | 2023-2024 | Mounjaro, Zepbound |
| Eisai INC. | $34.99 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $30.27 | 2025 | |
| Medtronic, INC. | $29.53 | 2022-2025 | Inceptiv |
| Regeneron Healthcare Solutions, INC. | $29.42 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.09 | 2019-2023 | |
| Argenx US, INC. | $26.99 | 2023 | Vyvgart |
| Amarin Pharma, INC. | $24.68 | 2021 | |
| Pfizer INC. | $23.75 | 2021-2022 | |
| Banner Life Sciences, LLC | $23.50 | 2024 | |
| Aroa Biosurgery Incorporated | $22.95 | 2020 | |
| Emd Serono, INC. | $21.50 | 2023 | Mavenclad |
| Esperion Therapeutics, INC. | $21.05 | 2021 | |
| Neurocrine Biosciences, INC. | $20.12 | 2023 | Ingrezza, Ongentys |
| Radius Health, INC. | $17.82 | 2024 | Tymlos |
| Insightec,INC | $16.19 | 2025 | Exablate |
| Grifols USA, LLC | $16.09 | 2023 | Xembify |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2021 | |
| Baxter Healthcare | $14.88 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Axsome Therapeutics, INC. | $13.80 | 2023 | Auvelity |
| Novartis Pharmaceuticals Corporation | $12.52 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.